Turning Point Therapeutics

Turning Point Therapeutics is a clinical-stage structure-based drug design company for the discovery and development of precision medicines for cancer and other diseases.  They focus on the design of novel chemical identities for established oncogene drivers with secondary resistant mutations, newly identified disease-driven targets, and potential targets regulating the tumor microenvironment and tumor immunity.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN DIEGO, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (Nasdaq: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the closing of its previously announced underwritten public offering of 5,287,357 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 689,655 shares, at a price to the public of $87.00 per share. The gross proceeds to Turning Point from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Turning Point, were approximately $460.0 million.

Turning Point Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares in Public Offering of Common Stock

SAN DIEGO, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (Nasdaq: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the pricing of its previously announced underwritten public offering of 4,597,702 shares of its common stock at a price to the public of $87.00 per share. The gross proceeds to Turning Point from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Turning Point, are expected to be approximately $400.0 million. In addition, Turning Point has granted the underwriters a 30-day option to purchase up to an additional 689,655 shares of common stock. The offering is expected to close on or about October 29, 2020, subject to satisfaction of customary closing conditions.

Turning Point Therapeutics Announces Pricing of $400 Million Public Offering of Common Stock

SAN DIEGO, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (Nasdaq: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell $400,000,000 of shares of its common stock. In connection with the offering, Turning Point expects to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the shares of common stock offered in the public offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Turning Point Therapeutics Announces Commencement of Public Offering of Common Stock

SAN DIEGO, Oct. 24, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today reported initial clinical data from the ongoing Phase 1 dose finding portion of its SHIELD-1 study of drug candidate, TPX-0022, a potent inhibitor of MET and the associated cancer signaling pathways of SRC and CSF1R. The initial data highlighted preliminary clinical activity, including objective responses across multiple tumor types and a generally tolerable safety profile.

Turning Point Therapeutics Presents Initial Clinical Data From Phase 1 SHIELD-1 Study of Novel MET/SRC/CSF1R Inhibitor TPX-0022 at 2020 EORTC-NCI-AACR Symposium

Discussion to Include Initial Phase 1 Data from Ongoing SHIELD-1Trial of TPX-0022 Discussion to Include Initial Phase 1 Data from Ongoing SHIELD-1Trial of TPX-0022

Turning Point Therapeutics to Host Conference Call to Discuss Presentations at 2020 EORTC-NCI-AACR Virtual Symposium

SAN DIEGO, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that an abstract for the TRIDENT-1 clinical study of its lead drug candidate repotrectinib has been selected for a mini-oral presentation on Jan. 31, 2021 at the International Association for the Study of Lung Cancer (IASLC) 2020 World Conference on Lung Cancer.

Turning Point Therapeutics Announces Abstract For TRIDENT-1 Clinical Study of Repotrectinib Accepted For Presentation at World Conference on Lung Cancer

Two Additional Abstracts Selected for Poster Presentations of Preclinical Data for Lead Drug Candidate Repotrectinib Two Additional Abstracts Selected for Poster Presentations of Preclinical Data for Lead Drug Candidate Repotrectinib

Turning Point Therapeutics Announces Early Clinical Data For Novel MET Inhibitor TPX-0022 Selected For Late-Breaker Oral Presentation at 32nd EORTC-NCI-AACR Symposium

SAN DIEGO, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis, M.D., will participate in a question and answer session on Oct. 5 as part of the Roth Capital Partners’ CEO Talk Series.

Turning Point Therapeutics to Participate in Upcoming Virtual Investor Conference

SAN DIEGO, Sept.  21, 2020  (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis, M.D., will participate in two question and answer sessions at the H.C. Wainwright Virtual Precision Oncology Conference on Sept. 24.

Turning Point Therapeutics to Participate in H.C. Wainwright Precision Oncology Investor Conference

Preeminent Leaders in Cancer Signaling Pathways and Dysregulated Protein Kinases to Advise Company’s Early Pipeline Development Preeminent Leaders in Cancer Signaling Pathways and Dysregulated Protein Kinases to Advise Company’s Early Pipeline Development

Turning Point Therapeutics Announces Scientific Advisory Board

SAN DIEGO, Aug.  24, 2020  (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the Food and Drug Administration (FDA) granted a third Fast-Track designation to its lead drug candidate, repotrectinib.

Turning Point Therapeutics Granted Fast-Track Designation for Repotrectinib in NTRK-Positive TKI-Pretreated Advanced Solid Tumors

Turning Point Therapeutics (TPTX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Turning Point Therapeutics (TPTX) Looks Good: Stock Adds 5.3% in Session

SAN DIEGO, Aug.  19, 2020  (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today reported early interim data from the registrational Phase 2 TRIDENT-1 study of lead drug candidate, repotrectinib, and announced recent regulatory feedback from the Food and Drug Administration (FDA) on the TRIDENT-1 trial design.

Turning Point Therapeutics Reports Early Interim Data From Registrational Phase 2 Trident-1 Study of Repotrectinib, Provides Regulatory Update

Turning Point Therapeutics (TPTX) delivered earnings and revenue surprises of 14.58% and -100.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Turning Point Therapeutics (TPTX) Reports Q2 Loss, Lags Revenue Estimates

SAN DIEGO, July  27, 2020  (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of Heather Adams as vice president of Human Resources, effective today. Ms. Adams has more than 20 years of human resources experience, primarily in the health care industry across multiple biotechnology and medical device companies.

Turning Point Therapeutics Names Heather Adams as Vice President of Human Resources

SAN DIEGO, July  13, 2020  (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of Andrew Partridge as executive vice president and chief commercial officer, effective today. Mr. Partridge has more than 20 years of global pharmaceutical sales and marketing experience leading more than 20 commercial launches across multiple indications, including oncology, hematology and rare diseases.

Turning Point Therapeutics Names Andrew Partridge As Executive Vice President and Chief Commercial Officer

Zai Labs will pay up to $176 million for the rights to sell repotrectinib in the Greater China market.

Turning Point Therapeutics Licenses Its Lung Cancer Drug in China

Next Generation ALK Inhibitor Candidate, TPX-0131, Overcomes ALK Resistant Mutations in Preclinical Models Next Generation ALK Inhibitor Candidate, TPX-0131, Overcomes ALK Resistant Mutations in Preclinical Models

Turning Point Therapeutics’ Lead Drug Candidate Repotrectinib Increases Effectiveness of KRAS-G12C and MEK Inhibitors in Preclincal KRAS Cancer Models

SAN DIEGO, May  27, 2020  (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (Nasdaq: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that the underwriters of its previously announced underwritten public offering of its common stock have exercised in full their option to purchase 812,500 additional shares of common stock at the public offering price of $60.00 per share. The initial sale of 5,416,667 shares of common stock was completed on May 21, 2020 and the sale of the additional 812,500 shares is expected to close on or about May 28, 2020, subject to satisfaction of customary closing conditions. The total gross proceeds to Turning Point from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Turning Point, are expected to be approximately $373.8 million.

Turning Point Therapeutics Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Common Stock

SAN DIEGO, May  18, 2020  (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (Nasdaq: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the pricing of its previously announced underwritten public offering of 5,416,667 shares of its common stock at a price to the public of $60.00 per share. The gross proceeds to Turning Point from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Turning Point, are expected to be approximately $325.0 million. In addition, Turning Point has granted the underwriters a 30-day option to purchase up to an additional 812,500 shares of common stock. The offering is expected to close on or about May 21, 2020, subject to satisfaction of customary closing conditions.

Turning Point Therapeutics Announces Pricing of $325 Million Public Offering of Common Stock

Turning Point Therapeutics (NASDAQ: TPTX) shares are trading higher on Wednesday.

Why Turning Point's Stock Is Trading Higher Today

Turning Point Therapeutics, Inc. (TPTX) CEO Athena Countouriotis on Q1 2020 Results - Earnings Call Transcript

SAN DIEGO, May  12, 2020  (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today reported financial results for the first quarter ended Mar. 31 and provided operational updates, including measures taken by the company in response to the COVID-19 pandemic.

Turning Point Therapeutics Reports First-Quarter Financial Results, Provides Update on Operations and COVID-19 Response

As of late, it has definitely been a great time to be an investor Turning Point Therapeutics

Will Turning Point Therapeutics Continue to Surge Higher?

Turning Point Therapeutics (TPTX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

News for Turning Point Therapeutics Stock (TPTX)